为教条提供证据:COVID-19鼻腔筛查拭子后鼻出血的风险
本研究采用配对设计,纳入2020年4月至2021年3月期间在单一整合医疗系统内接受单次COVID鼻腔拭子检测的所有患者,比较拭子后7天(危险期)与拭子前7天(对照期)的鼻出血发生率。共纳入827,987名参与者,发生1047次鼻出血就诊,危险期鼻出血患病率为0.08%,对照期为0.04%,拭子暴露与危险期鼻出血风险增加相关(OR 1.92,95%CI 1.73-2.12)。作者结论认为COVID鼻腔拭子与鼻出血风险增加相关,医生应告知患者,尤其是具有既往面部外伤、抗凝/抗血小板药物使用或高血压等高危因素的患者。
要点
- COVID鼻腔拭子后7天鼻出血患病率为0.08%,拭子前7天为0.04%。
- 拭子暴露与鼻出血风险增加相关,OR为1.92(95%CI 1.73-2.12)。
- 高龄、亚裔/太平洋岛民、男性、高血压、既往面部外伤及抗凝药使用与鼻出血风险增加相关。
核心结论
- COVID鼻腔拭子与鼻出血风险增加相关。
- 医生应告知患者,尤其是具有既往面部外伤、抗凝/抗血小板药物使用或高血压等高危因素的患者。
研究设计与样本
- 采用配对设计。
- 研究在单一整合医疗系统内进行。
- 纳入2020年4月至2021年3月期间在本机构接受单次COVID鼻腔拭子检测的所有患者。
- 共纳入827,987名参与者,发生1047次鼻出血就诊。
主要发现
- 危险期(拭子后7天)鼻出血患病率为0.08%,对照期(拭子前7天)为0.04%。
- 拭子暴露与危险期鼻出血风险增加相关,OR为1.92(95%CI 1.73-2.12)。
- 高龄、亚裔/太平洋岛民(相比白人)、男性、高血压、既往面部外伤以及华法林或直接口服抗凝药使用与鼻出血风险显著增加相关(p ≤ 0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is anecdotal evidence SARS-CoV-2 (COVID) RT-PCR screening nasal swabs confer an elevated epistaxis risk. We aimed to assess the association between epistaxis and exposure to a COVID nasal swab. STUDY DESIGN: A matched pairs design was used. SETTING: The study was performed in a single, integrated health care system. METHODS: All patients who received a single COVID nasal swab at our institution between April 2020 and March 2021 were included. McNemar's test was used to compare rates of epistaxis between the 7 days following the index COVID swab (hazard period), and the 7 days preceding the index COVID swab (control period). Conditional logistic regression was used to evaluate sociodemographic and clinical risk factors for epistaxis. RESULTS: A total of 827,987 participants were included, with 1047 epistaxis encounters. The prevalence of epistaxis during the hazard and control periods were 0.08% and 0.04%, respectively. Swab exposure was associated with 1.92-fold odds of epistaxis during the hazard period (95% confidence interval [1.73, 2.12]). Older age, Asian/Pacific Islander (PI) (compared to white), male sex, hypertension, prior facial trauma, and warfarin or direct-acting oral anticoagulant use were also associated with significantly increased odds of epistaxis (p ≦ 0.01). CONCLUSION: COVID nasal swabs are associated with increased odds of epistaxis. Physicians should counsel patients, particularly those at the highest risk, including a history of prior facial trauma, anticoagulants/antiplatelets, or hypertension.
引用
- Block-Wheeler NR, Wei J, Weintraub MR, et al. Providing Evidence for Dogma: Risk of Epistaxis After COVID-19 Nasal-Screening Swab. Otolaryngol Head Neck Surg. 2023. PMID: 36939470. doi:10.1002/ohn.253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。